Ultromics features in the top 10 breakthroughs in healthcare…
£50m Innovate UK funding programme announced to realise the government’s Life Sciences strategy – and improve NHS diagnostics
Ultromics establishes the largest ongoing clinical trial programme of its kind
A recent report published by Frost & Sullivan has analysed the medical imaging AI market and ranked the top start-ups by funding amounts and country of origin. Ultromics has been ranked number nine globally.
Ultromics is excited to announce our latest investor, Woodford Investment Management, who have added £1m to our recently closed £10m Series A round. Woodford Investment Management joins a group of leading investors including Oxford Sciences Innovation, RT Ventures, Tanarra Capital and GT Healthcare.
The increasing pace of development in digital innovations aims to put patients in charge of their health and care and offer new ways to address the challenges of an ageing population, but how are entrepreneurs changing the world of healthcare with the help of technology?
Almost a third of all human deaths in the world are caused by cardiovascular disease (CVD), so encouraging news about breakthrough developments in diagnoses powered by machine-learning is enough to make your heart skip a beat.
Innovations in biotech are pushing the frontiers of modern medicine at a rapid pace, with many of them being hatched inside tiny startups.
FOUR years ago a woman in her early 30s was hit by a car in London. She needed emergency surgery to reduce the pressure on her brain. Her surgeon, Chris Mansi, remembers the operation going well. But she died, and Mr Mansi wanted to know why. He discovered that the problem had been a four-hour delay in getting her from the accident and emergency unit of the hospital where she was first brought, to the operating theatre in his own hospital…
UK start-up Ultromics has developed echocardiography analysis technology called Topological Analysis that claims to reduce errors diagnosing coronary artery disease by as much as 75%
Ultromics, the UK start-up behind breakthrough artificial intelligence (AI) technology for the diagnosis of coronary heart disease, has raised £10 million in Series-A investment. The funding was led by Oxford Sciences Innovation (OSI), with Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal investors Andre Crawford-Brunt and Dieter Spälti also participating.